Kuros Biosciences (KURN) AI Stock Analysis

• Market Cap: CHF1.05B
• Dividend Yield: N/A
• Average Volume (3M): 166.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.60
• Revenue Growth: 104.01%
• EPS Growth: 33.25%
• Country: CH
• Employees: 122
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 38,936,220
• 10 Day Avg. Volume: 215,314
• 30 Day Avg. Volume: 166,042
• PEG Ratio: 2.90
• Price to Book (P/B): 13.52
• Price to Sales (P/S): 10.51
• P/FCF Ratio: 391.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF32.52
• Price Target Upside: 14.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 58 Neutral
• Price Target: CHF25.00 ▼(-12.22% Downside)

The overall score reflects strong financial stability and revenue growth, but is weighed down by negative profitability and bearish technical indicators. The lack of earnings call data and corporate events further limits positive sentiment.

Kuros Biosciences Business Overview & Revenue Model

Company Description

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

How the Company Makes Money

Kuros Biosciences generates revenue through the commercialization of its regenerative medicine products, which are sold to healthcare providers and institutions for use in surgical procedures. The company earns income from the sale of its core products, which include bone graft substitutes and other regenerative therapies. Additionally, Kuros may engage in strategic partnerships and collaborations with larger pharmaceutical or medical device companies, which can provide upfront payments, milestone payments based on development progress, and royalties on future sales. These partnerships not only enhance the company's financial stability but also expand its market reach and accelerate product development.

Kuros Biosciences Financial Statement Overview

Summary

Kuros Biosciences shows strong revenue growth and improved cash flows, but faces challenges with negative profit margins and return on equity. The balance sheet is robust with low debt levels, providing stability.

Income Statement

The company has demonstrated strong revenue growth with a remarkable increase from CHF 33.56 million in 2023 to CHF 75.55 million in 2024. The gross profit margin is healthy at 82.09%. However, the net profit margin remains negative at -4.92%, indicating the company is still incurring losses. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows strength with a significant equity base, as indicated by the equity ratio of 69.46%. The debt-to-equity ratio is low at 0.03, suggesting minimal leverage. The return on equity remains negative at -6.32%, reflecting the company's current unprofitability.

Cash Flow

Cash flow from operations has improved significantly, turning positive in 2024 to CHF 3.14 million. The free cash flow also shows a positive trend, indicating better cash management. The free cash flow to net income ratio is positive, suggesting efficient cash conversion despite net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	107.19M	75.56M	33.56M	17.99M	13.81M	4.04M
Gross Profit	94.89M	62.03M	23.94M	10.77M	10.07M	1.67M
EBITDA	2.13M	-561.00K	-6.84M	-8.84M	-5.29M	-8.58M
Net Income	-6.09M	-3.72M	-13.73M	-14.60M	-7.54M	-11.52M
Balance Sheet
Total Assets	109.97M	84.54M	71.46M	82.95M	91.34M	94.36M
Cash, Cash Equivalents and Short-Term Investments	17.90M	17.46M	14.21M	24.07M	28.62M	28.39M
Total Debt	1.79M	1.79M	2.14M	1.91M	2.15M	2.34M
Total Liabilities	33.32M	25.79M	14.75M	14.09M	14.36M	9.76M
Stockholders Equity	76.65M	58.75M	56.71M	68.86M	76.98M	84.60M
Cash Flow
Free Cash Flow	-787.00K	2.03M	-9.17M	-7.75M	-5.83M	-9.46M
Operating Cash Flow	779.00K	3.14M	-8.84M	-7.35M	-5.45M	-9.24M
Investing Cash Flow	-1.57M	-1.11M	-326.00K	-400.00K	-374.00K	-220.00K
Financing Cash Flow	1.65M	1.34M	-171.00K	3.22M	6.08M	17.08M

Kuros Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 28.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:KURN, the sentiment is Positive. The current price of 28.48 is above the 20-day moving average (MA) of 24.65, above the 50-day MA of 25.90, and above the 200-day MA of 23.97, indicating a bullish trend. The MACD of 0.73 indicates Negative momentum. The RSI at 66.93 is Neutral, neither overbought nor oversold. The STOCH value of 90.81 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:KURN.

Kuros Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NWRN	69 Neutral	$281.45M	11.76	―	―	744.64%	―
BSLN	68 Neutral	CHF618.77M	8.45	―	―	58.51%	―
KURN	58 Neutral	CHF1.05B	―	-7.82%	―	104.01%	33.25%
MOLN	52 Neutral	$119.91M	―	-48.90%	―	-91.34%	-2.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IDIA	51 Neutral	CHF1.02B	―	―	―	67.18%	-480.10%
SANN	38 Underperform	$140.31M	2.58	-301.13%	―	-56.85%	-186.55%

Kuros Biosciences Corporate Events

Kuros Biosciences Achieves 82% Sales Growth in Q1 2025

Kuros Biosciences reported an 82% year-over-year increase in sales for the first quarter of 2025, with total medical device sales reaching USD 28.8 million. The company achieved a significant milestone with monthly revenues surpassing USD 10 million for the first time. Kuros is proactively expanding its global footprint, with MagnetOs products gaining commercial clearance in Brazil and Lebanon, and is taking strategic steps to mitigate potential impacts from upcoming U.S. tariffs by increasing inventory and diversifying production. Recent clinical studies have demonstrated high fusion rates for MagnetOs in high-risk patients, further validating its efficacy and supporting the company’s growth momentum.